Axitinib, a kind of tyrosine kinase inhibitor, could increase the expression of NKG2D on NK cells via DNA damage response (DDR) induction, which promoted NK cell recognition and degranulation in a reactive oxygen species (ROS)-dependent manner in RCC immune response (Morelli et al., 2015). This evidence concerns the gene KLRK1 and renal cell carcinoma.